The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: Effects of psychotropic drugs

Molecular Psychiatry

Volumn 7, Issue 10, 2002, Pages 1107-1114

  Kim, Y K ^a   Suh, I B ^a   Kim, H ^a   Han, C S ^a   Lim, C S ^a   Choi, S H ^b   Licinio, J ^c  

^a Korea University College of Medicine   (South Korea)

^b Yongin Mental Hospital   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytokine; Inflammatory response system; Interleukin 12; Major depression; Mania; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; CLOZAPINE; EMONAPRIDE; FLUOXETINE; HALOPERIDOL; INTERLEUKIN 12; LITHIUM; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; RISPERIDONE; VALPROIC ACID; VENLAFAXINE;

ADULT; AGED; ARTICLE; BIPOLAR MANIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; TH1 CELL; TIME;

ADOLESCENT; ADULT; AGED; BIPOLAR DISORDER; DEPRESSIVE DISORDER; FEMALE; HUMANS; INTERLEUKIN-12; MALE; MIDDLE AGED; PSYCHOTROPIC DRUGS; REFERENCE VALUES; SCHIZOPHRENIA; TH1 CELLS;

EID: 12244252752     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001084     Document Type: Article

References (61)

1. Smith RS. Is schizophrenia caused by excessive production of interleukin-2 and interleukin-2 receptors by gastrointestinal lymphocyte? Med Hypotheses 1991; 34: 225-229.
2. Smith RS, Maes M. The macrophage-T lymphocyte theory of schizophrenia: Additional evidence. Med Hypotheses 1995; 45: 135-141.
3. Maes M, Smith RS, Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995; 20: 116-120.
4. Maes M, Bosmans E, Meltzer H, Scharpe S, Suy E. Interleukin-1®: A putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 1993; 150: 1189-1193.
5. Maes M. Evidence for an immune response in major depression: A review and hypothesis. Prog NeuroPsychopharmacol Biol Psychiatry 1995; 19: 11-38.
6. Muller N, Riedel M, Ackenheil M, Schwarz MJ. The role of immune function in schizophrenia: An overview. Eur Arch Psychiatry Clin Neurosci 1999; 249: 62-68.
7. Wilke I, Arolt V, Rothermundt M, Weitzsch CH, Hornberg M, Kirchner H. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1996; 246: 279-284.
8. Ganguli R, Yang Z, Shurin G, Chengappa KNR, Brar JS, Gubbi AV et al. Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness. Psychiatry Res 1994; 51: 1-10.
9. Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, Berger M. Interleukin-6 (IL-6] plasma levels in depression and schizophrenia: Comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997; 247: 228-233.
10. van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK. Elevated interleukin-6 in schizophrenia. Psychiatry Res 1999; 87: 129-136.
11. Tananka KF, Shintani F, Fujii Y, Yagi G, Asai M. Serum interleukin-18 levels are elevated in schizophrenia. Psychiatry Res 2000; 96: 75-80.
12. Ganguli R, Brar JS, Chengappa KNR, Deleo M, Yang ZW, Shurin G et al. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. Arch Gen Psychiatry 1995; 52: 668-672.
13. Kim YK, Lee MS, Suh KY. Decreased IL-2 production in Korean schizophrenic patients. Biol Psychiatry 1998; 43: 701-704.
14. Arolt V, Rothermundt M, Wandinger KP, Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 2000; 5: 150-158.
15. Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, Kirchner H. Immunological dysfunction in schizophrenia: A systematic approach. Neuropsychobiology 1998; 37: 186-193.
16. Mittleman BB, Castellanos FX, Jacobsen LK, Rapoport JL, Swedo SE, Shearer GM. Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol 1997; 159: 2994-2999.
17. van Kammen DP, McAllister-Sistilli CG, Kelley ME. Relationship between immune and behavioral measures in schizophrenia. In: Wieselmann G (ed). Current Update in Psychoimmunology. Springer Verlag Wien: NY, 1997, pp 51-55.
18. Cazzullo CL, Scarone S, Grassi B, Vismara C, Trabattoni D, Clerici M et al. Cytokine production in chronic schizophrenia patients with or without paranoid behavior. Prog NeuroPsychoPharmacol Biol Psychiatry 1998; 22: 947-957.
19. Kim YK, Kim L, Lee MS. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 2000; 44: 165-175.
20. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry 1993; 150: 1408-1410.
21. McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME et al. Increases in CSF levels of IL-2 in schizophrenia: Effects of recurrence of psychosis and medication status. Am J Psychiatry 1995; 152: 1291-1297.
22. Cazzullo CL, Sacchetti E, Galluzzo A, Panariello A, Colombo F, Zagliani A et al. Cytokine profiles in drug-naive schizophrenic patients. Schizophr Res 2001; 47: 293-298.
23. Maes M. Major depression and activation of the inflammatory response system. In: Dantzer R et al (eds). Cytokines, Stress and Depression. Plenum: New York, 1999, pp 1-24.
24. Connor TJ, Leonard BE. Depression, stress and immunological activation: The role of cytokines in depressive disorders. Life Sci 1998; 62: 583-606.
25. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: Central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999; 4: 317-327.
26. Dantzer R, Wollman E, Vitkovic L, Yirmiya R. Cytokines and depression: Fortuitous or causative association? Mol Psychiatry 1999; 4: 328-332.
27. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Ear Neuropsychopharmacol 2001; 11: 203-208.
28. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interlkin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers. J Psychatr Res 1995; 29: 141-152.
29. Rapaport MH, Guylai L, Whybrow P. Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J Psychiatry Res 1999; 33: 335-340.
30. Tsai SY, Chen KP, Yang YY, Chen CC, Lee JC, Singh VK et al. Activation of indices of cell-mediated immunity in bipolar mania. Biol Psychiatry 1999; 45: 989-994.
31. Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W et al. Acute phase proteins in schizophrenia, mania and major depression: Modulation by psychotropic drugs. Psychiatry Res 1997; 66: 1-11.
32. Leykin I, Mayer R, Shinitzky M. Short and long term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 1997; 37: 75-86.
33. Maes M, Bosmans E, Ranjan R, Vandoolaeghe E, Meltzer HY, De Ley M et al. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: Effects of antipsychotic drugs. Schizophr Res 1996; 21: 39-50.
34. Maes M, Bosman E, Kenis G, De Jongh R, Smith RS, Meltzer HY. In viva immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 1997; 26: 221-225.
35. Maes M, Song C, Lin AH, Bonaccorso S, Kenis G, DeJongh R et al. Negative immunoregulatory effects of antidepressants: Inhibition of interferon-© and stimulation of interleukin-10 secretion. Neuropsychopharmacology 1999; 20: 370-379.
36. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U et al. The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses. Annu Rev Immunol 1998; 16: 495-521.
37. Stern AS, Magram J, Presky DH. Interlukin-12: An integral cytokine immune response. Life Sci 1996; 58: 639-854.
38. Trinchieri G. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13: 251-276.
39. Trinchieri G. Immunobiology of interleukin-12. Immunol Res 1998; 17: 269-278.
40. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edn). American Psychiatric Press: Washington DC, 1994.
41. First MB, Gibbon M, Spitzer RL, Williams JBW. Structural Clinical Interview for DSM-IV Research Version. Biometric Research Department, New York Psychiatric Institute: New York, 1998.
42. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962; 10: 799-812.
43. Hamilton M. A rating scale for depression. J Neural Neurosurg Psychiatry 1960; 23: 56-62.
44. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
45. Muller N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders. Prog NeuroPsychopharmacol Biol Psychiatry 1998; 22: 1-33.
46. McAdams C, Leonard BE. Neutrophil and monocyte phagocytosis in depressed patients. Prog NeuroPsychopharmacol Biol Psychiatry 1993; 17: 971-984.
47. Schwarz MJ, Ackenheil M, Riedel M, Muller N. Blood-CSF barrier impairment as indicator for an immune process in schizophrenia. Neurosci Lett 1998; 253: 201-203.
48. Lin A, Kenis G, Bignotti S, Tara GJB, DeJong R, Bosmans E et al. The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6. Schizophr Res 1998; 32: 9-15.
49. Sluzewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann NY Acsd Sci 1995; 762: 474-476.
50. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Cytokine production and serum proteins in depression. Scand J Immunol 1995; 41: 535-538.
51. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 2001; 21: 199-206.
52. Song C, Lin Ah, Kenis G, Bosmans E, Maes M. Immunosuppressive effects of clozapine and haloperidol: Enhanced production of the interleukin-1 receptor antagonist. Schizophr Res 2000; 42: 157-164.
53. Maes M, Chiavetto LB. Bignotti S, Tura GJB, Pioli R, Boin F et al. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 2000; 10: 119-124.
54. Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine. Acts Psychiatr Scand 1994; 89: 346-351.
55. Pollmacher T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996; 16: 403-409.
56. Nikkila HV, Muller K, Ahokas A, Miettien K, Rimon R, Andersson LC. Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes. Am J Psychiatry 1999; 156: 1725-1729.
57. Sluzewska A, Sobieska M, Rybakowski JK. Changes in acute phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology 1997; 35: 123-127.
58. Rapaport MH, Manji HK. The effects of lithium on ex vivo cytokine production. Biol Psychiatry 2001; 50: 217-224.
59. Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kuhn M, Schuld A et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis. J Psychiatric Res 1999; 33: 407-418.
60. Riches P, Gooding R, Millar BC, Rowbottom AW. Influence of collection and separation of blood samples on plasma IL-1, 1L-6 and TNF-α concentrations. J Immunol Meth 1992; 153: 125-131.
61. De Jongh R, Vranken J, Vundelinckx G, Bosmans E, Maes M, Heylen R. The effects of anticoagulation and processing on assays of IL-6, sIL-6R, sIL-2R and soluble transferrin receptor. Cytokine 1997; 9: 696-701.